Details der Publikation - Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis

Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis

Purpose The purpose of this study was to estimate the risk and severity of oral and gastrointestinal mucosal toxicities associated with selected targeted agents. Methods We searched the English-language literature in February 2011 for reports of randomized clinical trials comparing a FDA-approved targeted agent to a standard of care regimens. Long-term follow-up and secondary reports of trials were excluded, leaving 85 studies for analysis. Using meta-analytic methods, we calculated the relative risks of oral and gastrointestinal toxicities, adjusting for sample size using the inverse variance technique. For each targeted agent and each side effect, we calculated the number needed to harm, the number of patients that, if treated with the more toxic regimen, would produce one additional episode of the toxicity. Results Oral mucositis was significantly more frequent among patients treated with bevacizumab, erlotinib, sorafenib, or sunitinib, although this difference was confined to low-grade mucositis. The clinical significance of these findings is unclear given its low incidence and mild severity. In contrast, diarrhea was significantly more frequent with most of the targeted agents studied, with adjusted relative risks between 1.5 and 4.5. An additional patient with diarrhea will be observed for every three to five patients treated with these targeted agents, compared with conventional regimens. Conclusions Oral mucosal toxicities occasionally complicate treatment with these targeted agents, but the clinical significance of this finding is not clear. Diarrhea is a hallmark of treatment with these targeted agents; this side effect should be carefully ascertained to permit early intervention and control..

Medienart:	E-Artikel

Erscheinungsjahr:	2013
Erschienen:	2013

Enthalten in:	Zur Gesamtaufnahme - volume:21
Enthalten in:	Supportive care in cancer - 21(2013), 11 vom: 02. Mai, Seite 3243-3254

Sprache:	Englisch

Beteiligte Personen:	Elting, Linda S. [VerfasserIn] Chang, Yu-Chia [VerfasserIn] Parelkar, Pratibha [VerfasserIn] Boers-Doets, Christine B. [VerfasserIn] Michelet, Marisol [VerfasserIn] Hita, Guido [VerfasserIn] Rouleau, Tanya [VerfasserIn] Cooksley, Catherine [VerfasserIn] Halm, Josiah [VerfasserIn] Vithala, Madhuri [VerfasserIn] Bossi, Paolo [VerfasserIn] Escalante, Carmen [VerfasserIn] Brennan, Michael T. [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Themen:	Diarrhea Meta-analysis Mucositis Stomatitis Systematic review Targeted therapy Toxicity

RVK:	RVK Klassifikation ELIB24

Anmerkungen:	© Springer-Verlag Berlin Heidelberg 2013

doi:	10.1007/s00520-013-1821-8

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC210706380X

Internformat


LEADER	01000caa a22002652 4500
001	OLC210706380X
003	DE-627
005	20230502113501.0
007	cr uuu---uuuuu
008	230403s2013 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s00520-013-1821-8 \|2 doi
035			\|a (DE-627)OLC210706380X
035			\|a (DE-He213)s00520-013-1821-8-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a ELIB24 \|q VZ \|2 rvk
100	1		\|a Elting, Linda S. \|e verfasserin \|4 aut
245	1	0	\|a Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis
264		1	\|c 2013
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Springer-Verlag Berlin Heidelberg 2013
520			\|a Purpose The purpose of this study was to estimate the risk and severity of oral and gastrointestinal mucosal toxicities associated with selected targeted agents. Methods We searched the English-language literature in February 2011 for reports of randomized clinical trials comparing a FDA-approved targeted agent to a standard of care regimens. Long-term follow-up and secondary reports of trials were excluded, leaving 85 studies for analysis. Using meta-analytic methods, we calculated the relative risks of oral and gastrointestinal toxicities, adjusting for sample size using the inverse variance technique. For each targeted agent and each side effect, we calculated the number needed to harm, the number of patients that, if treated with the more toxic regimen, would produce one additional episode of the toxicity. Results Oral mucositis was significantly more frequent among patients treated with bevacizumab, erlotinib, sorafenib, or sunitinib, although this difference was confined to low-grade mucositis. The clinical significance of these findings is unclear given its low incidence and mild severity. In contrast, diarrhea was significantly more frequent with most of the targeted agents studied, with adjusted relative risks between 1.5 and 4.5. An additional patient with diarrhea will be observed for every three to five patients treated with these targeted agents, compared with conventional regimens. Conclusions Oral mucosal toxicities occasionally complicate treatment with these targeted agents, but the clinical significance of this finding is not clear. Diarrhea is a hallmark of treatment with these targeted agents; this side effect should be carefully ascertained to permit early intervention and control.
650		4	\|a Mucositis
650		4	\|a Stomatitis
650		4	\|a Diarrhea
650		4	\|a Targeted therapy
650		4	\|a Toxicity
650		4	\|a Meta-analysis
650		4	\|a Systematic review
700	1		\|a Chang, Yu-Chia \|4 aut
700	1		\|a Parelkar, Pratibha \|4 aut
700	1		\|a Boers-Doets, Christine B. \|4 aut
700	1		\|a Michelet, Marisol \|4 aut
700	1		\|a Hita, Guido \|4 aut
700	1		\|a Rouleau, Tanya \|4 aut
700	1		\|a Cooksley, Catherine \|4 aut
700	1		\|a Halm, Josiah \|4 aut
700	1		\|a Vithala, Madhuri \|4 aut
700	1		\|a Bossi, Paolo \|4 aut
700	1		\|a Escalante, Carmen \|4 aut
700	1		\|a Brennan, Michael T. \|4 aut
773	0	8	\|i Enthalten in \|t Supportive care in cancer \|d Springer Berlin Heidelberg, 1993 \|g 21(2013), 11 vom: 02. Mai, Seite 3243-3254 \|h Online-Ressource \|w (DE-627)254909574 \|w (DE-600)1463166-0 \|w (DE-576)074754076 \|x 1433-7339 \|7 nnns
773	1	8	\|g volume:21 \|g year:2013 \|g number:11 \|g day:02 \|g month:05 \|g pages:3243-3254
856	4	0	\|u https://dx.doi.org/10.1007/s00520-013-1821-8 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_267
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2134
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	r	v	\|a ELIB24
951			\|a AR
952			\|d 21 \|j 2013 \|e 11 \|b 02 \|c 05 \|h 3243-3254

Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände